Please login to the form below

Not currently logged in
Email:
Password:

Boehringer in antibody partnership

Boehringer Ingelheim has signed a deal with MacroGenics to develop therapies based on MacroGenics' antibody technology platform

Boehringer Ingelheim has signed a deal with the privately held biotechnology company MacroGenics to develop and commercialise therapies based on MacroGenics' antibody technology platform.

Under the global alliance, the companies will work together to discover, develop and commercialise therapeutics in areas such as immunology, oncology, respiratory, cardiometabolic and infectious diseases. The drug candidates will be based on MacroGenics' Dual-Affinity Re-Targeting (DART) biospecific antibody technology platform and will be directed against up to 10 combinations of molecular targets.

The companies will have joint responsibility for discovery and some preclinical activities, with Boehringer Ingelheim taking full responsibility for all subsequent preclinical, clinical, regulatory, commercial and manufacturing activities.

MacroGenics will likely receive about $60m during the first several years of the partnership, with that figure consisting of an upfront cash payment, annual maintenance fees, R&D funding, and near-term research-based milestones. The company also stands to receive milestone payments that could theoretically total $210m for each of the 10 development programmes in case of full commercial success of multiple DART products.

The deal calls for MacroGenics to receive tiered royalties on net product sales and gives the company the option to co-promote certain DART products in the US. In addition, as the partnership progresses, Boehringer Ingelheim also expects to make an equity investment in the company.

MacroGenics, which was founded about a decade ago, is based in Rockville, Maryland. The company's lead product is teplizumab, an antibody that is in phase III trials for the treatment of autoimmune diseases under a partnership with Lilly.

27th October 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics